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Abstract Objective: To empirically
test, based on a large multicenter,
multinational database, whether
a modified PIRO (predisposition, in-
sult, response, and organ dysfunction)
concept could be applied to predict
mortality in patients with infection
and sepsis. Design: Substudy of
a multicenter multinational cohort
study (SAPS 3). Patients: A total of
2,628 patients with signs of infection
or sepsis who stayed in the ICU for
> 48 h. Three boxes of variables
were defined, according to the PIRO
concept. Box 1 (Predisposition) con-
tained information about the patient’s
condition before ICU admission.
Box 2 (Injury) contained information
about the infection at ICU admission.
Box 3 (Response) was defined as
the response to the infection, ex-
pressed as a Sequential Organ Failure
Assessment score after 48 h. Inter-
ventions: None. Main measurements
and results: Most of the infections
were community acquired (59.6%);
32.5% were hospital acquired. The
median age of the patients was 65
(50–75) years, and 41.1% were fe-
male. About 22% (n = 576) of the
patients presented with infection
only, 36.3% (n = 953) with signs of
sepsis, 23.6% (n = 619) with severe
sepsis, and 18.3% (n = 480) with
septic shock. Hospital mortality
was 40.6% overall, greater in those
with septic shock (52.5%) than in
those with infection (34.7%). Several
factors related to predisposition, in-
fection and response were associated
with hospital mortality. Conclusion:
The proposed three-level system, by
using objectively defined criteria for
risk of mortality in sepsis, could be
used by physicians to stratify patients
at ICU admission or shortly there-
after, contributing to a better selec-
tion of management according to the
risk of death.
Keywords Intensive care unit ·
Severity of illness · Infection ·
Sepsis · PIRO · Risk adjustment
Introduction
In 1991, the American College of Chest Physicians and
the Society of Critical Care Medicine held a consensus
conference to define the systemic inflammatory response
to infection (or sepsis), including sepsis-associated or-
gan dysfunction, hypoperfusion or hypotension (severe
sepsis) and sepsis-induced cardiovascular failure despite
adequate fluid resuscitation (septic shock) [1]. Criticized
by some [2], these definitions nevertheless became heavily
used by clinicians and researchers over the following
years.
In 2001, several European and American critical care
societies organized a second consensus conference to
address the weaknesses of these definitions and to improve
the early identification and stratification of patients with
sepsis [3]. The result of this conference was the adoption
of systemic inflammatory response syndrome as a broader
definition of inflammation. Furthermore, minor changes
were added to the definition of severe sepsis and septic
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shock. A new system for risk stratification that had
emerged from the Fifth Toronto Sepsis Roundtable in
Toronto, Canada in October 2000 [4] was also adopted:
the IRO system (insult, response, and organ dysfunction),
that later became the PIRO (with the addition of predis-
position) [5–8]. Although interesting and promising, this
approach remained virtually conceptual.
The objective of this study was to empirically test –
with the use of a large multicenter, multinational database
– whether a modified definition of PIRO (using the
concept of predisposition, infection, response, organ dys-
function/failure) could be useful for predicting mortality in
patients with infection and sepsis.
Materials and methods
Details about project organization, data collection and
cohort building were already presented in detail else-
where [9]. Data were collected at intensive care unit (ICU)
admission and on days 1, 2 and 3 and on the last day
of the ICU stay. Data from the day of admission were
collected within an hour before or after ICU admission,
as recently described. Severity of illness was assessed
using the SAPS 3 Admission Score [10]. On the fol-
lowing days of the ICU stay, further information was
collected: number and severity of organ dysfunction, as
measured by the Sequential Organ Failure Assessment
(SOFA) [11]; length of ICU and hospital stay; and out-
come data, including vital status at ICU and hospital
discharge.
From the SAPS 3 Hospital Outcome Cohort (com-
prising 16,784 patients from 303 ICUs), 3,505 patients
presented with an infection already at ICU admission
(20.9% of the SAPS 3 cohort). From these, patients with
a length of stay (LOS) in the ICU less than 48 h were
excluded (n = 877), resulting in a study cohort of 2,628
patients (Fig. 1). Infection, sepsis, severe sepsis and septic
shock were defined according to the published consensus
criteria by using the worst state at the time of ICU
admission [1]. Details about the formation of the SAPS 3
Hospital Outcome Cohort can be found elsewhere [9].
To test the PIRO concept in the SAPS 3 database, three
different logical boxes were defined:
Predisposition: The variables of the SAPS 3 Admission
Score Boxes 1 and 2, which are not related to infection,
were used. These include age, co-morbidities, use of va-
soactive drugs before ICU admission, intrahospital loca-
tion before ICU admission, length of stay in the hospi-
tal before ICU admission, reason(s) for ICU admission,
planned/unplanned ICU admission, surgical status at ICU
admission and, if applicable, the anatomic site of surgery.
Injury: For this box, all variables related to infection at
ICU admission were used. These include acquisition of the
infection, extension and site of infection, the presence of
bacteremia and the microbial agents identified.
Response: To identify the response to infection, we used
the development of organ dysfunction and failure, meas-
ured through the highest SOFA score values for each organ
system between 24 and 48 h after ICU admission.
The definitions of these variables can be found in Ap-
pendix C of the electronic supplementary material (ESM).
Because this was an observational study and no additional
interventions were performed, the need for informed con-
sent was waived by the institutional review board. Each
ICU coordinator, however, was responsible for obtaining
local permissions as necessary.
Data quality
Recorded data were evaluated for completeness of the doc-
umentation and reliability. Inter-rater quality control was
performed through rescoring of the data and calculation of
kappa coefficients and intra-class correlation coefficients,
as appropriate [12]. Data quality was excellent; results
were presented in detail in the ESM file of the SAPS 3
primary report [9].
Statistical analysis
Statistical analysis was performed using the SAS system,
version 8e (SAS Institute, Cary, NC, USA). A p-value
of < 0.05 was considered significant. Unless otherwise
specified, results are expressed as median and interquartile
ranges (quartile). Observed-to-expected (O/E) mortality
ratios were calculated by dividing the number of observed
deaths per group by the number of expected deaths per
group (as predicted by the SAPS II). To test for statistical
significance, we calculated 95% confidence intervals
(CI) according to the method described by Hosmer and
Lemeshow [13]. The Hosmer–Lemeshow goodness-of-fit
Hˆ- and Cˆ-statistics [14] were used to evaluate the calibra-
tion of the developed prognostic model. Discrimination
was tested by measuring the area under the receiver
operating characteristic curve (aROC), as described by
Hanley and McNeil [15].
Model development
Variables were selected according to their association with
hospital mortality. To select significant predictors, we ran-
domly extracted five roughly equal-sized parts based on
ICUs from the database, as previously described in de-
tail [9]. It was thus possible to run the model-building pro-
cedure five times, each time taking four parts of the sample
as a development set and the fifth as the validation set. This
allowed us to estimate the variability, and thus the stability,
of the prediction.
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The criterion for a predictor to enter the model was
homogeneity across the five model-building processes:
in principle, predictors should enter the model in all five
development sets, but depending on the frequency of the
predictor in the samples, the magnitude of the effect, and
medical reasoning, some predictors were included if they
appeared in the model in at least three subsamples. The
quality of predictions in the validation sets was assessed
by looking at the goodness-of-fit and the discriminative
capability of the models. Variable selection was further
confirmed by bootstrapping – drawing random data
sets with replacement from our training set (n = 2,628
observations), where each sample had the same size as our
original training set. This was done 100 times, producing
100 bootstrap data sets.
Using the parameter estimates from the logistic regres-
sion as starting values, a multilevel model (logistic regres-
sion with random effects) was applied in the next step,
using patient characteristics as fixed effects and ICUs as
a random effect.
Results
The patients in the cohort under analysis had a median age
of 65 (50–75) years, and 41.1% were female. Approxi-
mately two thirds of the patients were admitted for med-
ical reasons and one third after elective or acute surgery.
Overall hospital mortality was 40.6% (Table 1).
Of the patients admitted, 21.9% (n = 576) presented
with infection only, 36.3% (n = 953) with signs of sepsis,
23.6% (n = 619) with severe sepsis and 18.3% (n = 480)
with septic shock. ICU and hospital mortality rates
increased from those with infection to those with septic
shock (Table 1). Most (59.6%) of the infections were
community acquired, 32.5% hospital acquired (Table 2).
Further demographic details can be seen in the ESM
(Tables E1–E4).
The rate of disseminated versus localized infection
changed over the groups: localized infection was seen
in patients with infection without sepsis more often than
in patients with septic shock. In contrast, the rate of
disseminated infection increased with the progression of
infection to sepsis and septic shock (Table 2). The lower
respiratory tract was the most common site of infection
(48.9%), and the digestive tract was the second most
common site. Infection sites did not differ greatly among
the various subgroups (Table 2).
Overall, gram-positive bacteria were the causative
agents most often documented, followed by gram-negative
bacteria (“other”) (Table 3). However, for several agents,
distribution was different in the different groups: gram-
negative bacteria (“other”) were present more often in
patients with infection and showed decreasing incidence
in those with sepsis and those with septic shock and severe
sepsis. Details about the grouping of infective agents can Ta
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Table 3 Groups of infective agents
Cohort Infection Sepsis Severe sepsis Septic shock p-value
n % n % n % n % n %
Anaerobier 52 1.98 18 3.13 21 2.2 5 0.81 8 1.67 0.033
Fungi 156 5.94 27 4.69 52 5.46 47 7.59 30 6.25 0.163
Enterobacter 213 8.11 41 7.12 60 6.3 61 9.85 51 10.63 0.009
Escherichia 232 8.83 64 11.11 73 7.66 46 7.43 49 10.21 0.046
Gram-negative, other 280 10.65 75 13.02 98 10.28 60 9.69 47 9.79 0.212
Gram-positive, other 330 12.56 59 10.24 131 13.75 80 12.92 60 12.5 0.249
Intracellular 56 2.13 6 1.04 23 2.41 17 2.75 10 2.08 0.189
Staphylococci 238 9.06 57 9.9 75 7.87 59 9.53 47 9.79 0.456
Viruses 65 2.47 12 2.08 24 2.52 18 2.91 11 2.29 0.820
be found in the ESM (Table E5). Further demographic
details and mortality data for the patients excluded due to
a LOS ≤ 48 h can be found in the ESM (Table E6).
Overall hospital mortality in our study cohort was
40.6% (varying from 18.7% in patients with no infection
to 52.5% in patients with septic shock). The acquisition
of nosocomial infection versus community-acquired
infection was found to be associated with higher mortality
(35.5% in non-infected patients, 49.8% in patients with
hospital-acquired infections) at the time of ICU admission.
Fig. 1 Cohort development. HO, hospital outcome; LOS, length of stay
In the multivariate analysis, the following variables
turned out to be significant. Predisposition (Box 1): age;
location from which the patient was admitted to the ICU;
co-morbidities; length of stay before ICU admission
(days); and some reasons for ICU admission. Injury
(Box 2): acquisition of infection; extension of infection;
site of infection; and infective agent. Response (Box 3):
dysfunction of the renal and coagulation systems; failure
of the cardiovascular, respiratory, renal, coagulation and
central nervous systems (Table 4, scoresheet).
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The mean SAPS 3 PIRO score was 31.2 points (median
31, quartiles 22–39). The relationship between the SAPS 3
PIRO score and vital status at hospital discharge is given
by the equation:
Logit = −46.6757 + ln(SAPS 3 PIRO score
+ 76.7688) × 9.8797
and the probability of mortality by the equation:
Probability of death = e
logit
1 + elogit
Mean predicted mortality was 40.7% (median 39%,
quartiles 21–57%). Complete descriptive statistics for the
SAPS 3 PIRO score, corresponding predicted hospital
mortality and observed to expected mortality ratios in the
global cohort and in subgroups are presented in the ESM
(Tables E7 to E9).
Prognostic performance of the developed model
was tested by means of discrimination and calibration.
Calibration, as evaluated through the Hosmer–Lemeshow
goodness-of-fit test, was found to be excellent in the over-
all cohort (Cˆ-test: 3.51, p = 0.97; Hˆ-test: 5.33, p = 0.87) as
well as in the tested subgroups of infection, sepsis, severe
sepsis and septic shock (ESM, Appendix B). Discrimina-
tion was also very good, with an aROC of 0.772, better
than that of the SAPS 3 admission model in this cohort
(aROC: 0.735). For further details, see Appendix B of the
ESM.
Discussion
Sepsis, defined as the systemic reaction to infection [1],
remains an important cause of morbidity and mortality in
ICUS worldwide [16–18]. Despite the development of new
therapies and integrated approaches for diagnosis and care
of the patient with sepsis [19], mortality remains high [17].
Mortality seems, moreover, to be associated mainly
with the presence and amount of organ dysfunc-
tion/failure [20, 21]. This fact prompted several re-
searchers to propose a new method to classify sepsis,
which includes not only criteria for infection, but also
for predisposition of the patient and for the reaction of
the organism to the injury – the PIRO concept [4]. Since
that proposal, a number of researchers have tried to study
the predisposition and progression from sepsis to severe
sepsis and septic shock [22, 23], assuming that the organ
dysfunction/failure is just the final stage of the path that
leads to death.
We have modified the original concept. First, the devel-
opment of the SAPS 3 Admission Score clearly showed the
impact of predisposition on the outcome of patients. For
this reason we decided to keep predisposition in the model.
Second, in our understanding, the host response to the
insult and the resulting organ dysfunction cannot be
distinguished from each other. This is because – from
a pragmatic point of view – definitions of organ failure
incorporate a series of physiological and therapeutic
variables so that the evaluation of the response and the
evaluation of organ dysfunction/failure overlap. Perhaps
in the future specific biomarkers that announce the re-
sponse to infection may become available, allowing us
to detect the response of the organism to infection prior
to the development of organ dysfunction or failure. No
such markers are yet clinically available, however. Also,
some of these biomarkers may eventually be used to
predict the response to specific treatments, similarly to
but earlier than the baseline degree of organ dysfunction
(as has been demonstrated for a number of interventions,
including antibiotics, anti-TNF therapies and activated
protein C [24]). Altogether, this resulted in a three-level
staging model consisting of predisposition, injury and
response.
The SAPS 3 database represents a large cohort, com-
prising critically ill patients from several countries world-
wide, with a rate of infection or sepsis at ICU admission
(20.9%) comparable to other recent cohort studies such as
the European Sepsis Project [16]. Recently Vincent et al.
found an even higher incidence of 37.4%, but with a broad
variation between countries: from 18% in Switzerland to
73% in Portugal [25].
To test the concept of the response of the organism
to the injury (infection), we included only those patients
who stayed for > 48 h in the ICU. We did this to give
patients a minimum amount of time for response to be-
came evident. An evaluation at ICU admission or shortly
thereafter may highlight the insult but underestimate
the impact of the response. This inclusion criterion can,
however, represent a limitation of the present study, since
the SAPS 3 database registers and analyses only infections
present at ICU admission (excluding therefore patients
with ICU-acquired infection) and staying at least 48 h in
the ICU (which can exclude some patients that die from
sepsis very early after admission, particularly those with
septic shock; see Table E6).
Our results seem to confirm the hypothesis that the in-
cidence of severe sepsis and septic shock in the ICU is
increasing. This tendency has been consistently noted in
all recently published studies [17, 26, 27]. Physicians’ in-
creasing awareness of the early recognition and treatment
of sepsis, as a result of initiatives such as the Surviving
Sepsis Campaign [19], might in part explain this trend. On
the other hand, the increasing incidence became apparent
before these initiatives, so other factors, such as increas-
ing age, co-morbidities, characteristics of the infection or
the presence and amount of organ dysfunction and failure
at ICU admission, might be responsible for the observed
phenomenon.
Mortality for hospital-acquired infection in our cohort
was slightly lower than that reported by Friedman et al.
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(49.7%) [28], but higher than that reported in the Finnsep-
sis study (28.3%) [29]. The impact on mortality of nosoco-
mial sepsis versus community-acquired sepsis was similar
to the recently published results of Alberti et al. [16]. Some
factors related to the infection characteristics (such as the
site of infection, the microorganisms involved or the exten-
sion of the infection) have been demonstrated to be impor-
tant in the past. For example, aerobic gram-negative bac-
teria [22] or infection with Candida spp. [30] were found
to be associated with increased mortality. Our results add
to this evidence: Candida and other fungi remained a sig-
nificant predictor of mortality in the multivariate analysis
(Table 4). The number of cases of sepsis caused by fungal
organisms seems also to be increasing, with fungi being
responsible in our cohort for as many as 6.3% of the cases
of septic shock, as suggested previously [17].
Although several studies have addressed the question
of which factors affect the outcome of patients with sepsis,
we believe this is the first study in which the three levels of
predisposition, injury and response have been addressed
together. This approach allows for a better adjustment of
different baseline characteristics of the populations being
evaluated: researchers are now able to compare patients
in three individual categories that have been found to
be important for prognosis in addition to the aggregate
score. The way these categories of prognostic factors
interact to lead to death, mediated by the development of
multiple organ dysfunction/failure, is complex and will
certainly depend on various other factors, such as the
genetic background and the type and timing of eventual
therapeutic interventions. Since organ dysfunction/failure
is currently defined in the SOFA score by a combination
of physiological and therapeutic variables (e.g., blood
pressure and/or use of vasoactive agents), it is at this
time extremely difficult to dissociate consequences of the
injury from the response to therapeutic interventions. It
should be noted that in this system to model the risk of
mortality from sepsis, different weights were attributed to
specific organ failures (with more importance attributed to
CNS, renal and coagulation failures than to cardiovascular
or respiratory failures), contrary to the original SOFA, in
which all organ failures had the same weight. The use of
these three levels of prognostic factors, with physiology
being accessed only by the presence and degree of organ
dysfunction/failure, makes the system conceptually differ-
ent from general outcome prediction models, such as the
SAPS 3 admission model [10]. Although these systems,
developed for application to heterogeneous populations of
critically ill patients, share some prognostic variables with
the PIRO model, they do not include information about
the insult (namely the characteristics of the infection), and
the degree of physiological derangement is accessed in
those models through the use of a heterogeneous group
of variables measured at ICU admission (a mixture of
physiological and therapeutic variables rather than the
presence and degree of organ dysfunction/failure as in
PIRO).
Many more factors have been identified as having
prognostic importance in patients with sepsis, such as
polymorphisms in genes encoding key inflammatory
molecules [31]. To date, however, these markers have not
been incorporated in clinical practice or in the design of
clinical trials. Possibly in the future, the Predisposition
box could and should be expanded to include such factors,
but it is too soon to know whether and when such markers
will be available.
In conclusion, the results of our study – the SAPS 3
PIRO score (Table 4) – could be used by physicians to
stratify patients at ICU admission or shortly thereafter,
contributing to a better selection of management according
to the risk of death. The proposed system should, however,
be prospectively validated in an independent cohort in
order to demonstrate its usefulness.
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